Galectins are an ancient family of lectins characterized by evolutionarily conserved amino acid sequences and β-galactoside recognition and binding sites. Galectin-3 (Gal-3) is one of 15 known galectins. This protein has important functions in numerous biological activities, including cardiac fibrosis and heart failure. In recent years, many studies have shown that Gal-3 is closely associated with acute myocardial infarction (AMI) and may be a promising biomarker for the assessment of severity as well as prognosis prediction in AMI patients, but controversy still exists. In this review, we summarize the latest literature on the relationship between Gal-3 and unstable plaques, the secretion kinetics of Gal-3 during the acute phase of AMI, and the value of Gal-3 in the prediction of post-AMI remodeling. Finally, the possible value of Gal-3 as a biological target for AMI therapy is examined.
CITATION STYLE
Li, M., Yuan, Y., Guo, K., Lao, Y., Huang, X., & Feng, L. (2020, August 1). Value of Galectin-3 in Acute Myocardial Infarction. American Journal of Cardiovascular Drugs. Adis. https://doi.org/10.1007/s40256-019-00387-9
Mendeley helps you to discover research relevant for your work.